Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.
Vishal A. Patel, MD
Articles by Vishal A. Patel, MD
Dr Vishal A. Patel discusses innovative strategies for optimizing cemiplimab in treating high-risk cutaneous squamous cell carcinoma and enhancing patient outcomes.
Dr Patel highlights the groundbreaking C-POST trial results, showcasing cemiplimab's significant impact on disease-free survival in high-risk CSCC patients.
Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved cemiplimab, addressing significant patient needs.
Dr Vishal A. Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.
Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.